Ergoteles’s CRISPR Therapeutics CRSP Stock Holding History

Ergoteles’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,226	Closed	-$851K	–	1288
2021 Q4	$851K	Sell	11,226 -41,480	-79%	-$3.62M	0.03%	465
2021 Q3	$5.9M	Buy	52,706 +7,399	+16%	+$929K	0.22%	127
2021 Q2	$7.33M	Sell	45,307 -80,804	-64%	-$9.83M	0.17%	170
2021 Q1	$15.4M	Buy	+126,111	New	+$19M	0.48%	59

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ergoteles's CRSP Position: Q1 2022 in Review

Ergoteles sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 11,226 shares — an estimated $851K sold.

Ergoteles first reported a position in CRSP in Q1 2021 and held it in 4 quarters. The position peaked at $15.4M in Q1 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Ergoteles reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Ergoteles sold 11,226 CRISPR Therapeutics shares in Q1 2022, an estimated $851K.
Ergoteles first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 4 quarters.
Ergoteles's CRISPR Therapeutics position peaked at $15.4M in Q1 2021.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.